Serum and blood based biomarkers for lung cancer screening: a systematic review.

ABSTRACT:

Background

Lung cancer is the second most common cancer and the leading cause of cancer death for both men and women. Although low-dose CT (LDCT) is recommended for lung cancer screening in high-risk populations and may decrease lung cancer mortality, there is a need to improve the accuracy of lung cancer screening to decrease over-diagnosis and morbidity. Blood and serum-based biomarkers, including EarlyCDT-lung and microRNA based biomarkers, are promising adjuncts to LDCT in lung cancer screening. We evaluated the diagnostic performance of EarlyCDT-lung, micro-RNA signature classifier (MSC), and miR-test, and their impact on lung cancer-related mortality and all-cause mortality.

Methods

References were identified using searches of PubMed, EMBASE, and Ovid Medline® from Jan

SUBMITTER: Chu GCW 

PROVIDER: S-EPMC5812229 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature